Mintz is acting as legal advisor to Myriad Genetics, Inc. (NASDAQ: MYGN), a genetic testing and precision medicine company, in its proposed sale of Myriad RBM, Inc., which specializes in contract research services for the pharmaceutical industry, to Q2 Solutions, a global clinical trial laboratory services organization, and a wholly owned subsidiary of IQVIA. The transaction is expected to close in the third quarter of 2021.
Headquartered in Salt Lake City, Myriad Genetics is dedicated to advancing health and wellbeing for all, empowering individuals with vital genetic insights and enabling healthcare providers to better detect, treat and prevent disease. The company discovers and commercializes genetic tests that determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where genetic testing can significantly improve patient care and lower healthcare costs.
The Mintz team advising Myriad Genetics in the transaction is led by Member and Co-chair of the firm’s Retail and Consumer Products Practice Robert Burwell and has included Member and Chair of the firm’s Health Law and Health Care Enforcement Defense Practices Karen Lovitch, Member and Chair of the firm’s Privacy & Cybersecurity Practice Cynthia Larose, Members Dianne Bourque, Scott Pinarchick, Alexander Trimble, Jessica Catlow, and Robert Kidwell, Special Counsel Farrah Short, Of Counsel Benjamin Zegarelli, and Associate Maarten Tuurenhout.
Mintz is one of the leading law firms to the life sciences industry. The firm’s attorneys advise hundreds of businesses and other organizations across the sector’s ecosystem—from start-ups and emerging growth companies to large public companies as well as venture capital and private equity firms, investment banks, and research and academic institutions—on pivotal deals, mission-critical disputes, intellectual property, and regulatory matters. Learn more about Mintz’s Life Sciences Practice here.